A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Insulin degludec/liraglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Hefei,Beijing,Beijing,ChongQing,Fuzhou,Fuzhou,Guangzhou,Guangzhou,Guangzhou,Cangzhou,Shijiazhuang,Shijiazhuang,Changzhou,Huai'an,Huai'an,Nanjing,Nanjing,Nanjing,Zhenjiang,Nanchang,Changchun,Dalian,Yin, China
- Phase
- Phase 3
- Start date
- May 26, 2017
- End date
- Jul 13, 2019
- Enrollment
- 720 participants
Change in HbA1c
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin
 degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes
 mellitus inadequately controlled on oral antidiabetic agents
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03172494
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03172494 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 720 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.